On September 27, 2018 Geron Corporation (Nasdaq: GERN) reported that it will host a conference call to provide an update on the imetelstat collaboration with Janssen Biotech, Inc. (Janssen) on Thursday, September 27th at 8:00 a.m. ET (Press release, Geron, SEP 27, 2018, http://ir.geron.com/news-releases/news-release-details/geron-provide-update-imetelstat-collaboration-janssen-september [SID1234532270]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants may access the conference call live via telephone by dialing domestically +1 (877) 303-9139 or internationally +1 (760) 536-5195. The passcode is 7987354. Participants are advised to dial in at least 10 minutes prior to minimize any delay in joining the call. A live, listen-only webcast will also be available on the Company’s website at www.geron.com/investors/events. If you are unable to listen to the live call, an archived webcast will be available on the Company’s website for 30 days

On September 27, 2018 Sorrento Therapeutics, Inc (Nasdaq: SRNE, "Sorrento"), a clinical stage, antibody-centric, biopharmaceutical company developing new therapies reported that Henry Ji Ph.D,, Chairman, President and CEO will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Wednesday, October 3, 2018 at 2:30 PM ET at the Lotte New York Palace Hotel in New York, NY (Press release, Sorrento Therapeutics, SEP 27, 2018, View Source [SID1234532261]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 27, 2018 Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics), reported that Hui Liu, Ph.D., Executive Vice President, Chief Business Officer and Head of Merus U.S., will present a company overview at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018, at 4:00 p.m. ET (Press release, Merus, SEP 27, 2018, View Source;p=RssLanding&cat=news&id=2369315 [SID1234532117]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investors page of the Company’s website, View Source An archived presentation will be available for 90 days.

On September 27, 2018 2A Pharma is reported that we have been granted SEK 3M Eurostars funding for 2AP07 , a project to develop a therapeutic head and neck cancer vaccine in collaboration with The Danish Technological Institute and Danish biotech company DNA Sense (Press release, 2A Pharma, SEP 27, 2018, View Source [SID1234530716]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Head and neck cancers represents the sixth most common cancer worldwide, resulting in more than 350,000 deaths/year. Our AAVLP-HNC vaccine has the potential to minimize side effects, improve efficacy, and markedly reduce treatment costs. This will address an unmet medical need and benefit cancer patients as well as reduce healthcare expenses. In addition, our combination of advanced technologies will establish a versatile platform for developing further vaccines.

On September 27, 2018 Dynavax Technologies Corporation (NASDAQ:DVAX) reported that Eddie Gray, Dynavax’s Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018 at 10:40 AM ET at the InterContinental New York Barclay Hotel (Press release, Dynavax Technologies, SEP 27, 2018, View Source [SID1234530121]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and replayed versions of the webcast will be available on the "Events and Presentations" section of the Dynavax website at View Source